CDKN2A and melanoma: CDKN2A/B co-deletion was seen in 21 BMs (23.1% of cohort) across multiple cancer types including NSCLC (n = 9, 49.9%), melanoma (n = 6, 27.3%), breast (n = 2, 13.3%), gastrointestinal (n = 3, 25%), and renal cell carcinoma (n = 1, 25%) (Figure 1).